{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-025851","form_type":"8-K","ticker":"AAME","cik":"0000008177","company_name":"ATLANTIC AMERICAN CORP","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.067035+00:00","generated_at":"2026-06-02T01:35:21.248639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atlantic American Q1 net loss widens to $2.0M; premium revenue falls 3.4%","bullets":["Net loss of $2.0M ($0.10 per share) vs. loss of $1.4M ($0.08) in Q1 2023.","Premium revenue decreased $1.5M to $44.6M, down 3.4% year-over-year.","Operating loss of $2.4M compared to operating income of $0.6M a year ago.","Life and health operations drove the loss on lower premiums and unfavorable claims; P&C performed well.","Management highlighted new business initiatives and expanded sales in Atlantic Capital Life Assurance."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-025851","json":"https://secwatch.observer/filing/0001140361-24-025851.json","markdown":"https://secwatch.observer/filing/0001140361-24-025851.md","text":"https://secwatch.observer/filing/0001140361-24-025851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/8177/000114036124025851/0001140361-24-025851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/8177/000114036124025851/ef20029014_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:35:21.248639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d43514ce853c20c1f8ecc54c130624d21c6fbd","claim":"ATLANTIC AMERICAN CORP reported first quarter ended March 31, 2024 results: revenue $44.6 million, net income net loss of $2.0 million, or ($0.10) per common share, EPS ($0.10) per common share.","evidence_excerpt":"coupled with unfavorable loss experience in the life and health operations. Premium revenue for the three month period ended March 31, 2024 decreased $1.5 million, or 3.4%, to $44.6 million from $46.1 million in the three month period ended March 31, 2023. The Company reported operating loss (as defined below) of $2.4 million in the three month period ended March","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/8177/000114036124025851/0001140361-24-025851-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$44.6 million"},{"label":"Net income","value":"net loss of $2.0 million, or ($0.10) per common share"},{"label":"EPS","value":"($0.10) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}